<DOC>
	<DOCNO>NCT00898118</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . PURPOSE : This research study look blood sample young patient cytopenia undergo donor stem cell transplant .</brief_summary>
	<brief_title>Studying Blood Samples Young Patients With Cytopenia After Donor Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : Primary - To study hematopoietic chimerism whole blood different cell population ( i.e. , CD14 , CD15 , CD 56 , CD3 , CD19 ) well dendritic cell regulatory T cell allogeneic hematopoietic stem cell transplantation reduce intensity conditioning patient refractory cytopenia . - To compare result chimerism obtain standard short tandem nucleotide polymorphism PCR ( sensitivity 1 % ) obtain single nucleotide polymorphism PCR ( sensitivity 0.1- 0.01 % ) . Secondary - To evaluate relationship mixed chimerism hematological engraftment , overall survival , event-free survival . - To study impact mixed chimerism plasmacytoid dendritic regulatory T cell incidence acute chronic graft-versus-host-disease . OUTLINE : This multicenter study . Peripheral blood collect patient donor prior hematopoietic stem cell transplantation ( HSCT ) . Patients also undergo blood sample collection day 30 , 60 , 100 , 180 transplantation . Peripheral blood cell enrich separated lineage-specific subpopulation ( i.e. , CD3 , CD14 , CD15 , CD19 , CD56 ) divide equally either DNA isolation via PCR flow cytometry . DNA concentration pre-HSCT donor patient sample post-HSCT subpopulation sample determine use quantitative real-time PCR . Samples also analyze quantification chimerism detection genetic marker via short tandem repeats- sequence nucleotide polymorphism-based chimerism analysis .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosed refractory cytopenia Hypocellular bone marrow normal karyotype Underwent stem cell transplantation ( SCT ) HLA identical ( 8/8 ) sibling , HLA identical ( 10/10 ) relative , HLA identical single allelic disparate unrelated donor Received preparative regimen include either thiotepa fludarabine phosphate Concurrently enrol EWOGMDS2006 PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>